Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Ipsen Renegotiates 2010 Strategic Partnership Agreement With Inspiration

8/21/2012 1:09 AM ET

Ipsen (IPSEF.PK) announced the renegotiation of its 2010 strategic partnership agreement with Inspiration Biopharmaceuticals, Inc. for the development and commercialization of Inspiration's recombinant product portfolio - OBI-1, a recombinant porcine factor VIII (rpFVIII) being developed for treating patients with acquired hemophilia A and congenital hemophilia A with inhibitors, and IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B.

As per the new agreement and in its territories, Ipsen recovers commercial rights to OBI-1. Also, Ipsen is granted commercial rights for IB1001. As a result, Ipsen will record sales of OBI-1 and IB1001 in its drug sales line. Ipsen will further pay Inspiration a mid-teen royalty on OBI-1 sales and a higher double digit royalty on IB1001's sales.

In addition, under the new terms, Ipsen has agreed to invest up to $20 million in Inspiration.

Click here to receive FREE breaking news email alerts for Ipsen Promesses and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Starbucks Corp. said Thursday after the markets closed that its second quarter profit rose 9.4% from last year, helped by higher revenue. The company's quarterly earnings per share came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. The world's largest specialty coffee retailer also raised its full year earnings outlook. Software giant Microsoft Corp. said Thursday after the markets closed that its third quarter profit fell 6.6% from last year, when results were boosted by special upgrade offer revenues. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.